Genen­tech's tocilizum­ab short­age due to Covid-19 now hits CAR-T re­cip­i­ents, with FDA of­fer­ing al­ter­na­tives to help

Soon af­ter San Fran­cis­co-based Genen­tech won an EUA for tocilizum­ab as a treat­ment for hos­pi­tal­ized Covid pa­tients last sum­mer, the com­pa­ny an­nounced a short­age of the drug while point­ing to the emer­gence of the Delta vari­ant and the slow­ing of vac­ci­na­tion rates across the US.

“This new wave of the pan­dem­ic has led to Genen­tech ex­pe­ri­enc­ing an un­prece­dent­ed de­mand for Actem­ra IV– well-over 400% of pre-COVID lev­els over the last two weeks alone and it con­tin­ues to in­crease,” the com­pa­ny said in Au­gust.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER